The European Commission has added cannabigerol (CBG) to the EU's database for cosmetic ingredients (called “Cosing”), making the compound safe for use in health and beauty products.
European manufacturers of health and beauty products can now safely use cannabigerol or CBG from hemp in their cosmetics and skincare lines with the approval of a major market regulator for trade in the European Union.
The classification change was made by the EU Directorate-General for Internal Market, Industry, Entrepreneurship and SMEs (small and medium-sized enterprises).
CBG works with the CB1 and CB2 endocannabinoid receptors, which are located in the skin. Proponents say the hemp-derived compound has anti-inflammatory, antibacterial, and antioxidant properties that help the endocannabinoid system maintain healthy skin function.
Once CBG enters the epidermis, it penetrates the basal and subcutaneous layers of the skin where it helps to calm inflammation, reduce impurities, clear pores, balance oil production and improve cell turnover.
CBG is the 'Mother' cannabinoid
CBG is known as the 'mother' or 'OG' cannabinoid due to the fact that it is the precursor of all other cannabinoids such as CBD (Cannabidiol), CBN (Cannabinol), CBC (Cannabichromene), THC and THCA (Tetrahydrocannabinoleic Acid).
Naturally derived CBD, added to the Cosing database earlier this year, and synthetic CBD, are also approved for use in cosmetics in the EU, as is hemp leaves.
While cannabis stakeholders had long been developing THC and CBD, producers, researchers, and cannabis growers began exploring CBG a few years ago. Breeders have since developed various CBG-rich hemp cultivars.